N-(4-bromo-2,3-dichlorophenyl)-6-methoxy-7-(9H-[1,4]oxazino[3,4-c][1,4]oxazin-7-ylmethoxy)quinazolin-4-amine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: N-(4-bromo-2,3-dichlorophenyl)-6-methoxy-7-(9H-[1,4]oxazino[3,4-c][1,4]oxazin-7-ylmethoxy)quinazolin-4-amine
• 化学式: C₂₃H₁₇BrCl₂N₄O₄
• 分子量: 564.2
• InChiKey: UYFGWMZSDMKRGX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5
• 重原子数：
  34
• 可旋转键数：
  6
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  78
• 氢给体数：
  1
• 氢受体数：
  8

文献信息

• MEROCYANINE DERIVATIVES
  申请人：BASF SE

  公开号：US20140150380A1

  公开（公告）日：2014-06-05

  Disclosed are compounds of formula (1) and (2) and/or E/E-, E/Z- or Z/Z geometrical isomer forms thereof; wherein R1-R5, R1-R11 and A are defined as in description. The compounds are used as UV absorbers for protecting household products from photolytic and oxidative degradation, as plastic additives, preferably for food and pharmaceutical packaging applications, for preventing photo-degradation of food by incorporation of the compounds of formula (1′) and/or (2′) into transparent food containers, for protection of UV-A sensitive drugs from photo-degradation by incorporation of UV absorber in transparent blister foils or transparent pharmacy containers, as additives for photographic and printing applications, as additives for electronic applications and protecting the ingredients in agriculture applications.

  揭示的是公式（1）和（2）的化合物和/或其E/E-、E/Z-或Z/Z几何异构体形式；其中R1-R5、R1-R11和A的定义如描述中所述。这些化合物被用作紫外线吸收剂，用于保护家用产品免受光解和氧化降解，作为塑料添加剂，优选用于食品和药品包装应用，通过将公式（1'）和/或（2'）的化合物并入透明食品容器中，防止食物的光降解，通过在透明泡罩箔或透明药品容器中并入紫外线吸收剂，保护UV-A敏感药物免受光降解，作为摄影和印刷应用的添加剂，作为电子应用的添加剂，并保护农业应用中的成分。
• Receptor-Type Kinase Modulators and Methods of Use
  申请人：SYMPHONY EVOLUTION, INC.

  公开号：US20140155418A1

  公开（公告）日：2014-06-05

  The present invention provides compounds for modulating receptor kinase activity, particularly ephrin and EGFR, and methods of treating diseases mediated by receptor kinase activity utilizing the compounds and pharmaceutical compositions thereof. Diseases mediated by receptor kinase activity include, but are not limited to, diseases characterized in part by abnormal levels of cell proliferation (i.e. tumor growth), programmed cell death (apoptosis), cell migration and invasion and angiogenesis associated with tumor growth. Compounds of the invention include “spectrum selective” kinase modulators, compounds that inhibit, regulate and/or modulate signal transduction across subfamilies of receptor-type tyrosine kinases, including ephrin and EGFR.

  本发明提供了用于调节受体激酶活性的化合物，特别是ephrin和EGFR，并利用这些化合物和其制备的药物组合物治疗受受体激酶活性介导的疾病的方法。由受体激酶活性介导的疾病包括但不限于部分由细胞增殖异常水平（即肿瘤生长）、程序性细胞死亡（凋亡）、细胞迁移和侵袭以及与肿瘤生长相关的血管生成所特征化的疾病。本发明的化合物包括“光谱选择性”激酶调节剂，抑制、调节和/或调节受体型酪氨酸激酶亚家族的信号转导，包括ephrin和EGFR。
• US9359332B2
  申请人：——

  公开号：US9359332B2

  公开（公告）日：2016-06-07
• US9550730B2
  申请人：——

  公开号：US9550730B2

  公开（公告）日：2017-01-24